EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 343 filers reported holding EXELIXIS INC in Q3 2019. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $19,170,504 | -9.2% | 853,163 | -4.1% | 0.02% | -10.0% |
Q1 2024 | $21,112,222 | -6.9% | 889,688 | -5.8% | 0.02% | -16.7% |
Q4 2023 | $22,665,108 | +5.7% | 944,776 | -3.8% | 0.02% | -4.0% |
Q3 2023 | $21,452,312 | +11.6% | 981,802 | -2.4% | 0.02% | +13.6% |
Q2 2023 | $19,228,099 | +101281.9% | 1,006,180 | +3.0% | 0.02% | -4.3% |
Q1 2023 | $18,966 | +25.1% | 977,115 | +3.4% | 0.02% | +15.0% |
Q4 2022 | $15,156 | -99.9% | 944,908 | +1.6% | 0.02% | -9.1% |
Q3 2022 | $14,585,000 | -23.0% | 930,152 | +2.3% | 0.02% | -21.4% |
Q2 2022 | $18,933,000 | +1.3% | 909,351 | +10.3% | 0.03% | +16.7% |
Q1 2022 | $18,688,000 | +23.7% | 824,346 | -0.3% | 0.02% | +26.3% |
Q4 2021 | $15,107,000 | -10.1% | 826,437 | +4.0% | 0.02% | -17.4% |
Q3 2021 | $16,798,000 | +15.0% | 794,597 | -0.9% | 0.02% | +21.1% |
Q2 2021 | $14,602,000 | -21.4% | 801,434 | -2.6% | 0.02% | -24.0% |
Q1 2021 | $18,582,000 | +10.4% | 822,567 | -2.0% | 0.02% | +8.7% |
Q4 2020 | $16,839,000 | -19.4% | 838,989 | -1.8% | 0.02% | -30.3% |
Q3 2020 | $20,888,000 | +1.0% | 854,322 | -1.9% | 0.03% | -5.7% |
Q2 2020 | $20,676,000 | +45.3% | 870,933 | +5.4% | 0.04% | +16.7% |
Q1 2020 | $14,230,000 | +4.1% | 826,387 | +6.5% | 0.03% | +30.4% |
Q4 2019 | $13,674,000 | +1.7% | 776,049 | +2.1% | 0.02% | -8.0% |
Q3 2019 | $13,449,000 | -17.9% | 760,451 | -0.8% | 0.02% | -19.4% |
Q2 2019 | $16,381,000 | -13.5% | 766,558 | -3.7% | 0.03% | -16.2% |
Q1 2019 | $18,941,000 | +22.6% | 795,828 | +1.3% | 0.04% | +8.8% |
Q4 2018 | $15,447,000 | +47.9% | 785,306 | +33.2% | 0.03% | +70.0% |
Q3 2018 | $10,445,000 | -18.3% | 589,440 | -0.8% | 0.02% | -23.1% |
Q2 2018 | $12,782,000 | +82.4% | 593,969 | +87.7% | 0.03% | +73.3% |
Q1 2018 | $7,009,000 | -28.9% | 316,436 | -2.5% | 0.02% | -25.0% |
Q4 2017 | $9,863,000 | +21.2% | 324,449 | -3.4% | 0.02% | +11.1% |
Q3 2017 | $8,136,000 | +0.4% | 335,781 | +2.0% | 0.02% | 0.0% |
Q2 2017 | $8,105,000 | +56.4% | 329,053 | +37.6% | 0.02% | +50.0% |
Q1 2017 | $5,181,000 | +54.0% | 239,108 | +5.9% | 0.01% | +33.3% |
Q4 2016 | $3,365,000 | +24.5% | 225,711 | +6.8% | 0.01% | +28.6% |
Q3 2016 | $2,703,000 | +68.5% | 211,340 | +2.9% | 0.01% | +40.0% |
Q2 2016 | $1,604,000 | +129.8% | 205,330 | +17.6% | 0.01% | +150.0% |
Q1 2016 | $698,000 | -29.2% | 174,581 | -0.2% | 0.00% | -33.3% |
Q4 2015 | $986,000 | +16.0% | 174,856 | +15.3% | 0.00% | 0.0% |
Q3 2015 | $850,000 | +65.4% | 151,596 | +10.8% | 0.00% | +50.0% |
Q2 2015 | $514,000 | +18.2% | 136,795 | -19.1% | 0.00% | +100.0% |
Q1 2015 | $435,000 | +128.9% | 169,080 | +28.3% | 0.00% | 0.0% |
Q4 2014 | $190,000 | -5.5% | 131,780 | +0.3% | 0.00% | 0.0% |
Q3 2014 | $201,000 | -55.2% | 131,355 | -0.8% | 0.00% | 0.0% |
Q2 2014 | $449,000 | -5.5% | 132,455 | -1.2% | 0.00% | 0.0% |
Q1 2014 | $475,000 | -45.4% | 134,105 | -5.6% | 0.00% | -66.7% |
Q4 2013 | $870,000 | +5.7% | 141,995 | +0.4% | 0.00% | 0.0% |
Q3 2013 | $823,000 | +27.4% | 141,435 | -0.6% | 0.00% | +50.0% |
Q2 2013 | $646,000 | – | 142,266 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |